Skip to main content

Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics

NEW YORK (GenomeWeb) – Rosetta Genomics today announced that it has signed a deal to promote Precipio Diagnostics' oncology tests in certain US states, with plans to expand nationally later on.

Through a network of collaborations with Yale School and Medicine and other academic institutes, New Haven, Conn.-based Precipio offers a suite of molecular diagnostics that it tailors to patients' disease based on pathology and symptoms.

Under the agreement, Rosetta will promote Precipio's tests, including ones based on bone marrow and peripheral blood for hematologic cancers in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia, and Washington, DC, with an eye toward expanding nationally.

Rosetta said that the partnership is expected to help raise awareness about its own Cancer Origin Test, which analyzes patients' microRNA expression signatures to identify the source of cancers of unknown primary origin.

"We will promote the Precipio diagnostic services to the same doctors who also struggle with patients without a definitive diagnosis as to their cancers’ origin, which hampers decisions regarding optimal therapeutic approach," Rosetta President and CEO Kenneth Berlin said in a statement. "This partnership … allows us to provide more complete solutions for our customers and to optimize our commercial infrastructure."

Financial terms of the arrangement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.